Conversion from a basal-bolus insulin regimen to a GLP-1RA and basal insulin in type 2 diabetes

Many patients at the Advocate Aurora Family Medicine clinic are managed on basal bolus insulin. This regimen can be very complex and difficult to manage for many patients. In addition is it associated with many side effects such as hypoglycemia and weight gain.  A newer regimen recently incorporated in the ADA guidelines for the management of T2DM is the combination of a glucagon-like peptide-1 receptor agonist (GLP-1RA) plus basal insulin. GLP-1 is an incretin hormone which increases insulin secretion and decreases glucagon secretion in a glucose dependent manner, lowering the risk for hypoglycemia. GLP-1 also slows gastric emptying and improves satiety leading to potential weight loss.  GLP-1RA are generally well tolerated, with their most prominent negative effect being GI side effects. This presentation will review the two regimens and a retrospective case series performed at the Advocate Aurora Family Medicine clinic on patients that were successful and unsuccessful in converting from basal bolus insulin to a GLP-1 receptor agonist and basal insulin. 

Target Audience

This course is intended for family practice physicians, advance practice clinicians, and other members of the care team.

Learning Objectives

At the end of this session, learners should be able to:

  1. Identify the risks and benefits of transitioning a patient from basal bolus insulin to a regimen including a GLP-1 receptor agonist and basal insulin.
  2. Recognize if a patient would be a candidate for GLP-1 therapy. 
Additional information
AttachmentSize
Provider Summary.doc51.5 KB
Course summary
Available credit: 
  • 0.25 AMA PRA Category 1 Credit™
    Aurora Health Care is accredited by the Wisconsin Medical Society to provide continuing medical education for physicians. Aurora Health Care designates this activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
  • 0.25 Attendance
    Attendance Credit
Course opens: 
05/29/2019
Course expires: 
12/31/2020
Cost:
$0.00
Rating: 
0

Faculty

Course Director: Dennis Baumgardner, MD; Advocate Aurora Health 

Kelsey Gardetto, PharmD; Advocate Aurora Health 
Christopher Klink, PharmD, BCPS; Advocate Aurora Health 
Thomas Dilworth, PharmD, BCPS,  AQ-ID; Advocate Aurora Health 

Disclosure

The planners and speaker(s) have indicated that there are no financial relationships with any commercial interests to be disclosed.

Accreditation Statement

Advocate Aurora Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Advocate Aurora Health designates this internet enduring activity for a maximum of 0.25 AMA PRA Category 1 credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 0.25 AMA PRA Category 1 Credit™
    Aurora Health Care is accredited by the Wisconsin Medical Society to provide continuing medical education for physicians. Aurora Health Care designates this activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
  • 0.25 Attendance
    Attendance Credit

Accreditation Period

Course opens: 
05/29/2019
Course expires: 
12/31/2020

Price

Cost:
$0.00
Please login or register to take this course.

Please click “Take Course” to register for this program.   

Please contact the CME Office at cme@aurora.org or at (414) 219-5490 if you have any questions or need assistance.